Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Palvella Therapeutics to post earnings of ($0.58) per share for the quarter.
Palvella Therapeutics Stock Down 2.2 %
NASDAQ PVLA opened at $27.27 on Wednesday. The business has a fifty day moving average price of $19.36. The stock has a market capitalization of $306.00 million, a price-to-earnings ratio of -2.25 and a beta of 0.54. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27.
Analysts Set New Price Targets
A number of research firms have commented on PVLA. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. Jones Trading started coverage on shares of Palvella Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $45.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Finally, TD Cowen initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They set a “buy” rating and a $44.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $43.20.
Palvella Therapeutics Company Profile
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Are Penny Stocks a Good Fit for Your Portfolio?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- EV Stocks and How to Profit from Them
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
